Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study

Sydney Dubois1, Pierre-Julien Viailly1,2, Sylvain Mareschal1, Elodie Bothers1, Philippe Bertrand1, Philippe Ruminy1, Catherine Maingonnat1, Jean-Philippe Jais3, Pauline Peyrouze4, Martin Figeac4, Thierry J. Molina5, Fabienne Desmots5, Thierry Fest6, Corinne Haioun7, Thierry Lamy6, Christiane Copie-Bergman8, Josette Brière9,10, Tony Petrella11, Danièle Canioni12, Bettina Fabiani13, Bertrand Coiffier14, Richard Delarue15, Frédéric Peyrade16, André Bosly17, Marc André17, Nicolas Ketterer18, Gilles Salles14, Hervé Tilly1, Karen Leroy19, and Fabrice Jardin1

Abstract

Purpose: Next-generation sequencing (NGS) has detailed the genomic characterization of diffuse large B-cell lymphoma (DLBCL) by identifying recurrent somatic mutations. We set out to design a clinically feasible NGS panel focusing on genes whose mutations hold potential therapeutic impact. Furthermore, for the first time, we evaluated the prognostic value of these mutations in prospective clinical trials.

Experimental Design: A Lymphopanel was designed to identify mutations in 34 genes, selected according to literature and a whole exome sequencing study of relapsed/refractory DLBCL patients. The tumor DNA of 215 patients with CD20+/− DLBCL in the prospective, multicenter, and randomized LNH-03B LYSACl clinical trials was sequenced to deep, uniform coverage with the Lymphopanel. Cell-of-origin molecular classification was obtained through gene expression profiling with HGU133+2.0 Affymetrix GeneChip arrays.

Results: The Lymphopanel was informative for 96% of patients. A clear depiction of DLBCL subtype molecular heterogeneity was uncovered with the Lymphopanel, confirming that activated B-cell-like (ABC), germinal center B-cell like (GCB), and primary mediastinal B-cell lymphoma (PMBL) are frequently affected by mutations in NFκB, epigenetic, and JAK–STAT pathways, respectively. Novel truncating immunity pathway, ITKPB, MFHAS1, and XPO1 mutations were identified as highly enriched in PMBL. Notably, TNFAIP3 and GNA13 mutations in ABC patients treated with R-CHOP were associated with significantly less favorable prognoses.

Conclusions: This study demonstrates the contribution of NGS with a consensus gene panel to personalized therapy in DLBCL, highlighting the molecular heterogeneity of subtypes and identifying somatic mutations with therapeutic and prognostic impact.

Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common form of adult lymphoma worldwide, accounting for 30%–40% of newly diagnosed non-Hodgkin lymphoma (NHL; ref. 1). Gene expression profiling (GEP) has made strides in deciphering the molecular heterogeneity of DLBCL, enabling the entity's subdivision into three main molecular subtypes: germinal center B-cell like (GCB), activated B-cell like (ABC), and primary mediastinal B-cell lymphoma (PMBL; refs. 2, 3). Among other genetic aberrations, the GCB subtype is characterized by t(14;18)(q32;q21) translocations (4) and loss of PTEN (5), while the ABC subtype is characterized by t(3;14)(q27;q32) translocations, deletion of the INK4A-ARF locus (6), and BCL2 amplification (7). PMBL displays strong molecular similarities to classical Hodgkin lymphoma (cHL), exhibiting frequent amplifications of JAK2 and deletions of SOCS1 (8, 9). Arising from B cells at distinct stages of differentiation and maturation, these subtypes are also diverse in clinical presentation, response to immunochemotherapy, and outcome, with the ABC subtype having the most unfavorable prognosis (2, 7). As targeted therapies become increasingly widespread, it is essential to thoroughly characterize each molecular...
Translational Relevance

This is the first next-generation sequencing (NGS) study of such a large, prospective cohort using a targeted gene panel, the Lymphopanel, focusing on genes identified as important for lymphomagenesis or whose potential has been pinpointed in whole exome sequencing studies. Particular attention has been paid to the inclusion of actionable targets in the Lymphopanel, highlighting potential candidate patients for novel personalized therapies. This study further details subtype-enriched gene and pathway mutations to optimize DLBCL treatment, and highlights several novel, frequent, and actionable mutations, notably in PMBL. In addition, Lymphopanel NGS has enabled the detection of novel clinical and prognostic correlations, potentially impacting treatment decisions. As benchtop sequencers become increasingly available in academic research and routine clinical settings, our study demonstrates the feasibility and impact of NGS with a consensus gene panel in DLBCL patient management, contributing essential information to today’s precision therapy era treatment decisions.

NGS experiments and data analysis

The Lymphopanel was designed to identify mutations in 34 genes important for lymphomagenesis, based on literature data (Supplementary Table S2; ref. 24) and WES of relapsed/refractory DLBCL sequencing (25). The design covers 87,703 bases using (Supplementary Table S2), and detail the filters of artefacts and removed (filtered) variants of only 0.7% (Supplementary Table S4). Ion Torrent Personal Genome Machine (PGM) Sequencing and PGM data analysis was performed as described previously (26) and detailed in Supplementary Methods. Variant analysis was performed using an in-house generated bioinformatics pipeline, detailed in Supplementary Methods and Supplementary Fig. S1. This pipeline ensured excellent detailing the development of some of these recurrent SNVs, rendering the task of distinguishing driver mutations and passenger mutations even more challenging (23).

To more feasibly identify molecular subtypes and reach the goal of precision therapy in DLBCL, a limited and clinically relevant panel of target genes must be designed, with efforts made to thoroughly describe the SNVs they harbor. Furthermore, compact sequencers readily available in academic laboratories must be used to generalize this practice and apply it to routine clinical disease management. With this idea in mind, we developed a Lymphopanel NGS assay, designed to identify mutations in 34 genes important for lymphomagenesis based on a literature review of WES studies in DLBCL (13, 14, 20, 24) as well as a WES study of relapsed/refractory DLBCL cases (25). In the current study, we sequenced 215 patients with de novo DLBCL enrolled in the prospective, multicenter, and randomized LYSA LNH-03B trials, using the Lymphopanel. Our intent was to determine whether the Lymphopanel was informative enough to identify targetable SNVs and/or pathway mutations that might alter treatment decisions, highlight subtype-specific mutational profiles, distinguish genes impacted by AID, and potentially foretell clinical outcome.

Materials and Methods

Patients

215 adult patients with de novo CD20+ DLBCL enrolled in the prospective, multicenter, and randomized LNH-03B LYSA trials with available frozen tumor samples, centralized histopathologic review, and adequate DNA/RNA quality were selected. The LNH03-B LYSA trials were initiated in 2003 and included 1,704 patients overall in six distinct clinical trials (Supplementary Methods). COO molecular classification was obtained with HGU1332.0 AffymetrixGeneChip arrays (Affymetrix), grouping patients into ABC, GCB, PMBL, and "other," also referred to as unclassified (detailed in Supplementary Methods). Clinical features of the patients are indicated in Supplementary Table S1. The study was performed with approval of an Institutional review board and written informed consent was obtained from all participants at the time of enrollment.

Two-hybrid unsupervised clustering (supplementary LPS R package version 1.0.10) was performed using an in-house generated bioinformatics pipeline, detailed in Supplementary Methods and Supplementary Fig. S1 and S2. This pipeline ensured excellent filtering of artefacts and polymorphisms, as proven by an independent study of seven nontumoral samples from DLBCL patients with a mean error rate of nonfiltered variants of only 0.7% (Supplementary Table S4).

Statistical analysis

All statistical analyses were performed using R software version 3.1.2 (27). Progression-free survival (PFS) was evaluated from the date of enrollment to the date of disease progression, relapse, retreatment, or death from any cause. Overall survival (OS) was evaluated from the date of enrollment to the date of death from any cause. Multivariate Cox and log-rank tests (*survival* R package version 2.37.7) were used to assess differences in OS and PFS rates calculated by Kaplan–Meier estimates. Ward hierarchical unsupervised clustering (*hclust* R package version 1.0.10) was performed using Jaccard distance. Statistical differences between all other parameters were determined using $\chi^2$, Mann–Whitney, or Fisher exact tests as appropriate. $P$ values
Results and Discussion

Lymphopanel variant features

Lymphopanel NGS was performed on 215 DLBCL patients (81 ABC, 83 GCB, 33 "other," and 18 PMBL). The median overall sequencing depth was 225x (110x-331x). An initial 13,965 variants were filtered for quality, SNPs, and functional relevance, leading to 1,064 (7.6%) variants ultimately validated (Supplementary Table S5 and Supplementary Fig. S1). The Lymphopanel informativity was of 96%, with 206 patients (78 GCB, 80 ABC, 30 "other," and 18 PMBL) presenting at least one variant. All genes in the Lymphopanel were informative for at least one patient, with the number of variants per gene ranging from one to 124. Gene mutation frequencies in the total cohort and by subtype are presented in Fig. 1.

We subdivided the genes targeted by the Lymphopanel into eight specific pathways (Fig. 2; Supplementary Table S3). As expected, we confirmed that the ABC subtype is dominated by NFκB pathway mutations (45% of total variants), followed by epigenetic regulation pathway mutations (20.2% of total variants; Fig. 2A), whereas the GCB subtype is mostly characterized by mutations in the epigenetic regulation pathway (32.3% of total variants) and the apoptosis/cell-cycle pathway (26.3% of total variants; Fig. 2B). Mutations in the JAK–STAT, immunity, and apoptosis/cell-cycle pathways were prevalent in PMBL (29.1%, 20.9%, and 20.9% of total variants, respectively; Fig. 2C). Interestingly, PMBL presented a significantly higher number of variants per sample than the other subtypes combined ($P = 2.76 \times 10^{-5}$, Supplementary Fig. S3). Of 17 ABC patients with MYD88 L265P mutations, we found 10 (58.8%) of the three main subtypes, rather than the existence of a distinct entity.

We sought to assess the impact of AID involvement in the Lymphopanel genes (detailed in Supplementary Methods and Supplementary Fig. S4). Genes with an AID mutation frequency superior to the average of that of the Lymphopanel are presented in Supplementary Table S6. Previously identified SHM targets in DLBCL among these genes include MYC, PIM1, IRF4, BCL2, SOCS1, and CIITA (23). Potentially novel SHM targets include MFHAS1, PRDM1, GNA13, MYD88, ITPKB, and NOTCH2. There was no significant difference in AID involvement between DLBCL subtypes.

The Lymphopanel NGS identifies mutations with potential treatment impact

The Lymphopanel included genes whose mutations could serve to stratify patients according to treatment options. This includes actionable mutations, currently targeted by precision therapies, highlighted in Fig. 1, as well as mutations whose presence might call into question the use of certain targeted therapy options. Recent results have shown that doubly mutated MYD88/CD79B patients are significantly more responsive to single therapy ibrutinib, a BTK inhibitor, highlighting the importance of targeted NGS for DLBCL patients in the clinical setting (28). Furthermore, the presence of CARD11 and TNFAIP3 mutations has been shown to lead to decreased activity of both ibrutinib and sotrastaurin, a protein kinase C inhibitor (29, 30).

MYD88 mutations are frequent in ABC DLBCL, L265P being the most prevalent variant (up to 29% in previous studies; ref. 18). In our cohort, MYD88 mutations were significantly enriched in ABC patients (28.4%, FDR = 4.7×10^{-3}), with the L265P mutation present in 21% of ABC patients (Fig. 3 and Supplementary Fig. S5A). Of 17 ABC patients with MYD88 L265P mutations, we found 10 (58.8%)
with associated CD79B mutations, who might respond more favorably to Ibrutinib treatment. CD79B mutations were identified in 10.7% of total patients, slightly less than previously reported, but were significantly enriched in ABC DLBCL (24.7%, FDR = 3.2 × 10^{-5}), corroborating previous studies (13, 31). Of note, two (11.8%) MYD88 L265P–mutated ABC patients were CARD11-mutated and two were TNFAIP3-mutated, potentially diminishing the effect of ibrutinib and sotraustin, while 6 (35.3%) were PRDM1-mutated (Supplementary Fig. S6).

ABC cells have been shown to be addicted to IRF4 activity (32), responsible for lenalidomide treatment response. Twenty-one IRF4 variants were discovered in 7.9% of patients (13.6% of ABC, 4.8% of GCB, 0% of “other,” and 11.1% of PMBL; Fig. 1). Although the impact on expression of these mutations was not analyzed, only one IRF4 variant was a stop-gain mutation, indicating that expression is most likely at least conserved. Most of the nonsynonymous SNVs were clustered around amino acid positions 18 (two S18 variants and two G20 variants) and 99 (four C99R variants, SIFT scores=0; Fig. 4). Interestingly, IRF4 mutations were almost equally frequent in PMBL and ABC in our cohort. Although IRF4 addiction has not been demonstrated in PMBL, this predilection for IRF4 mutations, added to the well-known high expression of IRF4 in this subtype, may suggest a potential role for lenalidomide treatment in this subtype as well, calling for further investigation of these mutations’ effects.

Figure 2. Mutation pathway heterogeneity among DLBCL subtypes. Pie chart representations of mutation frequencies represented by pathway are represented for ABC (A), GCB (B), PMBL (C), and other (D) subtypes. Mutation frequencies per gene and per subtype are shown here as the percentage of the total number of variants. Genes were grouped into 8 specific pathways: Immunity (CIITA, B2M, TNFRSF14, and CD58), NOTCH (NOTCH1 and NOTCH2), Apoptosis/Cell Cycle (MEF2B1, XPO1, MYC, CDKN2A/B, FOXO1, TP53, GNA11, and BCL2), NF-kB (TNFAIP3, MYD88, PIM1, CARD11, IRF4, and PRDM1), Epigenetic Regulation (EZH2, KMT2D, EP300, MEF2B, and CREBBP), MAP Kinases (BRAF), JAK-STAT (SOCS1 and STAT3), and BCR (CD79A/B, ITPKB, TCF3, and ID3).

Recently, small-molecule inhibitors of PIM kinases have been developed and studied in DLBCL. In our cohort, PIM1 mutations were significantly skewed toward ABC (33.3%, FDR = 3.3 × 10^{-5}) in our cohort and represented 20.2% of ABC variants (Figs. 2A and 3 and Supplementary Fig. S5A). Of note, truncating PIM1 variants were predominant in ABC patients (13/14 identified). Interestingly, DLBCL sensitivity to PIM kinase inhibitors is not correlated with the level of PIM kinase expression (33), suggesting that even expression-modifying PIM1 mutations might not necessarily hamper the efficacy of PIM1 inhibitors, although this remains to be verified. In any case, the high frequency of PIM1 mutations in our cohort seems to justify the prescreening of PIM
kinase inhibitor candidate patients by PIM1 sequencing, to identify those most likely to benefit from this targeted therapy.

The most highly mutated gene in GCB, BCL2 (34), can notably be targeted by BH3-mimetics. Among our GCB cohort, BCL2 was the third most frequently mutated gene (24.1%, FDR = 2.5 × 10⁻³; Fig. 3 and Supplementary Fig. S5B), with mutations most frequently impacting the amino terminus and between the BH1 and BH3 domains. The BH3 domain was not impacted, indicating that BH3 mimetic activity would not be hampered in these patients (Supplementary Fig. S7).

Targeting epigenetic changes is also being increasingly explored in the realm of tailored therapy, notably among the GCB subtype, justifying the inclusion of genes such as EZH2, CREBBP, KMT2D, and EP300 within the Lymphopanel. In our cohort, 18.1% of GCB patients were EZH2 mutated, mostly at the Y641 hotspot, and EZH2 mutations were enriched in GCB (FDR = 1.8 × 10⁻³), as observed in previous studies, with no EZH2-mutated ABC patients (ref. 13; Fig. 3 and Supplementary Fig. S5B). Interestingly, one PMBL patient presented an EZH2 Y641 mutation, adding to the debate of which DLBCL subtypes might benefit from EZH2 inhibitor treatment (26). CREBBP mutations were identified in 31.3% of GCB patients and 6.2% of ABC patients, corroborating previous studies (17), but were also found in 24.2% of "other" and 11.1% of PMBL (Fig. 1 and Supplementary Fig. S5).

KMT2D mutations, evenly distributed throughout the coding sequence, were identified in 40.9% of our cohort, with KMT2D being the most frequently mutated gene in all subtypes except PMBL (Fig. 1). Of the 124 variants, 78 were truncating mutations, indicating bias toward loss of protein expression.

Mutations of master regulators TP53 and MYC showed no significant difference in subtype distribution in our cohort (Fig. 3).
TP53 variants were present in 14.9% of total patients (slightly less than previously reported; refs. 13, 35; Fig. 1) and several recurrent variants were identified, including six R248 variants, shown to be loss-of-function mutants in DLBCL (35). As for MYC, we discovered mutations in 6.5% of total patients (4.9% of ABC, 9.6% of GCB, 3% of “other,” and 5.6% of PMBL). No mutations were

Figure 4.
Mutations at the protein level. Protein representations were rendered using domains imported from the Pfam database (green). Exons were located using the CCDS database and were numbered automatically, not counting noncoding and spliced exons. Substitutions are depicted as diamonds, insertions as triangles, and deletions as rectangles whose length varies according to the deletion size. A color code is also applied, with blue indicating nonsynonymous substitutions or nonframeshift insertions, yellow indicating insertions and frameshift deletions, and pink indicating stop-gain and stop-loss mutations. Blue shading indicates sequenced regions.
identified at the known hotspots in Burkitt lymphoma, including S62 and T58.

Finally, although frequent mutations are most enticing for therapeutic potential, rare mutations can also be potentially very effectively actionable. For instance, BRAF and NOTCH1 mutations have been identified as rare but functionally relevant in DLBCL (13). In our cohort, we identified one patient with an activating V600E BRAF variant. As for NOTCH1, 10 patients in our cohort presented mutations (Fig. 1). TCF3 was mutated in three patients, all of whom harbored a pathogenic N551K variant, which has shown altered DNA-binding specificity (36). The negative regulator of TCF3, ID3, was mutated in 4.7% of patients (Fig. 1), with most variants affecting the HLH domain (Supplementary Fig. S7), potentially impairing its ability to inactivate TCF3, as shown in Burkitt lymphoma (36). ID3 and TCF3 mutations have recently been shown to be of comparable frequency in Burkitt lymphoma and DLBCL, highlighting the overlap between these two entities (37).

The Lymphopanel highlights a unique PMBL mutational signature

STAT6 and SOCS1 mutations were both very significantly enriched in PMBL (FDR = 6.8 × 10^{-14} and FDR = 2.5 × 10^{-9}, respectively), with STAT6 being the most frequently mutated gene in PMBL (72.2%, Fig. 3 and Supplementary Fig. S3). All STAT6 mutations were nonsynonymous SNVs and recurrent variants were frequent among PMBL, including seven N417 variants (Supplementary Fig. S7). SOCS1 mutations were present in 55.5% of PMBL patients, 30% of them harboring SOCS1-inactivating mutations (Supplementary Fig. S5). TNFAIP3 mutations have also been frequently identified in PMBL (up to 36%; ref. 38). We found TNFAIP3 mutations to be significantly enriched in PMBL (61.1%, FDR=3.1 × 10^{-10}), with all but one TNFAIP3-mutated PMBL patient harboring truncating mutations (Fig. 3 and Supplementary Fig. S3). The frequent TNFAIP3 and SOCS1 mutations in PMBL highlight the similarities between PMBL and chHL (38, 39). Furthermore, no MYD88, CD79B, or CARD11 mutations were observed in PMBL patients (Fig. 1), suggesting a PMBL dependence on TNFAIP3 mutations for the constitutive activation of NF-kB. Interestingly, significant GNA13 mutation enrichment was shown in PMBL rather than GCB in our cohort (50%, FDR = 2.8 × 10^{-4}; Fig. 3 and Supplementary Fig. S5), and one third of GNA13 variants were potentially truncating mutations (Fig. 4).

We discovered 46 B2M variants in 18.1% of total patients, significantly enriched in PMBL (50%, FDR = 1.2 × 10^{-5}; Figs. 1 and 3 and Supplementary Fig. S3C). Six of 9 B2M-mutated PMBL patients harbored truncating mutations and the remaining three presented pathogenic nonsynonymous SNVs, two of which were a highly recurrent p.M1R variant predicted to affect the start codon (Fig. 4). Recently, frequent B2M mutations leading to lack of protein expression were identified in chHL (9). Our similar findings in PMBL further highlight the molecular similarities between these two entities. CDS8 variants were also significantly enriched in PMBL (FDR = 1.2 × 10^{-3}; Fig. 3 and Supplementary Fig. S5), with 5 of 7 CDS8-mutated PMBL patients exhibiting truncating mutations, potentially leading to a lack of CDS8 expression. Importantly, PD-1 blockade has recently shown promise as an effective treatment of relapsed or refractory chHL (40). Escape from T-cell immunity via B2M and/or CDS8 mutations could potentially affect the activity of PD-1 inhibitors in PMBL and chHL and warrants further investigation. Furthermore, we found 39 CIITA variants, enriched in PMBL as well (55.6% of PMBL vs. 14.14% of total patients, FDR = 3.1 × 10^{-5}; Figs. 1 and 3 and Supplementary Fig. S3C). To our knowledge, this is the first study to identify truncating immunity pathway mutations as major in PMBL, although CIITA/PDL1-2 translocations had been shown to impact PMBL survival (41).

ITPKB, MHFAS1, and XPOJ mutations were identified as significantly overrepresented in a relapsed/refractory DLBCL patient cohort (25), leading to their inclusion in the Lymphopanel. In our cohort, ITPKB, MHFAS1, and XPOJ mutations were all identified for the first time as being significantly enriched in PMBL patients (FDR = 1.4 × 10^{-2}, FDR = 3.9 × 10^{-3}, and FDR = 4.8 × 10^{-10}, respectively; Fig. 3). The roles of ITPKB and MHFAS1 in lymphomagenesis are not yet fully elucidated. ITPKB regulates B-cell survival and function, and ITPKB deficiency leads to B-cell antigen presentation unresponsiveness and decreased B-cell survival, associated with specific overexpression of proapoptotic Bim protein (42). We found 48 ITPKB variants, present in 14% of total patients (Fig. 1 and Supplementary Fig. S5). ITPKB mutations were uniformly distributed along the protein sequence, excepting the seemingly conserved catalytic IPK domain, affected by only two nonsynonymous SNVs (Fig. 4). MHFAS1 is a potential oncogene with highly preserved leucine-rich tandem repeats, isolated from a minimal common amplified region in malignant fibrous histiocytomas at 8p23.1. MHFAS1 is also a target gene for chromosomal translocation (8;14) (p23.1;q21) in B-cell lymphoma cell lines and has been shown to be tumorigenic in nude mice (43). In our cohort, MHFAS1 variants were identified in 7.9% of total patients, and were distributed homogeneously along the coding sequence, with no recurrent mutations identified
Although the role of these potential oncogenes in lymphomagenesis is still unclear, their high mutation frequency in PMBL especially warrants further investigation.

As for XPO1, it encodes CRM1, an exporter of several tumor suppressor proteins (TSP). Cytoplasmic export of TSPs renders them inactive, indicating that XPO1 acts as a proto-oncogene. XPO1 mutations were present in 4.7% of total patients (1.2% of ABC, 1.2% of GCB, 3% of “other,” and 38.9% of PMBL; Fig. 1 and Supplementary Fig. S5). The mutation identified is recurrent, with all variants affecting E571 (Fig. 4), as previously found in rare CLL cases (<5%; ref. 44). Importantly, selective inhibitors of nuclear export (SINE) have been shown to effectively target CRM1 and retain TSPs in the nucleus (45). Given the frequency of XPO1 E571 mutations in PMBL, further investigation concerning their impact on response to SINEs is warranted (46).

Identification of gene mutations correlated with clinical characteristics and prognosis

We tested each gene in the Lymphopanel for correlation with clinical characteristics including age, stage, IPI, bone marrow involvement, and the presence of bulky disease.

CD79B, KMT2D, and MYD88 mutations were significantly correlated with age (Supplementary Fig. S8). For CD79B and MYD88 mutations, enriched in ABC, this might be linked to the significantly higher age of ABC patients (P = 1.01 × 10^{-7} in our cohort; ref. 47). As for KMT2D mutations, homogenous among subtypes, this result potentially suggests an accumulation of passenger-type mutations, particularly visible in this long gene (16.6 kb sequenced). MYD88 mutations were also significantly correlated with higher IPI (FDR = 0.04).

On the other hand, PMBL patients were significantly younger (P = 1.21 × 10^{-5}) and the large majority of genes whose mutations were significantly enriched in PMBL were also correlated with younger age (Supplementary Fig. S8). In addition, B2M and immunity pathway mutations were significantly inversely correlated with Ann Arbor stage (FDR = 3.2 × 10^{-3} and FDR = 0.045 respectively), and B2M and STAT6 mutations were significantly inversely correlated with IPI (FDR = 5.5 × 10^{-4} and FDR = 0.026, respectively).

As expected, OS and PFS decreased with increasing IPI and ABC patients displayed significantly worse OS and PFS than GCB patients in the R-CHOP treatment group (P = 1.9 × 10^{-5} and P = 6.6 × 10^{-3}, respectively; Supplementary Fig. S9). Of note, PMBL patients in our cohort did not present the favorable prognosis typically associated with this subtype (48), perhaps due to the lack of dedicated treatment.

Prognostic impact was assessed for all Lymphopanel genes and subtypes, among patients treated with R-chemotherapy, separated into an R-CHOP group and an R-ACVBP group. Analyses over all subtypes were performed using multivariate Cox tests, while analyses of each subtype individually were performed using log-rank tests. In both cases, independent corrections of P values
were signiﬁcant impacts. Of 0.05 to detect gene mutations with signiﬁcant prognostic impacts.

Among ABC DLBCL treated with R-CHOP, TNFAIP3 mutations were signiﬁcantly associated with lower OS (FDR = 7.86 × 10−10) and PFS (FDR = 3.04 × 10−7), while GNA13 mutations were signiﬁcantly associated with lower PFS (FDR = 3.04 × 10−2; Fig. 5). Of note, the poor prognostic impact of these mutations was not observed in patients treated with R-ACVBP, which, for TNFAIP3 at least, might be linked to the improved survival observed in younger patients with DLBCL treated with R-ACVBP (49). These ﬁndings need to be conﬁrmed in an independent cohort of patients, given the small sample size.

Unfortunately, the prognostic impact of TNFAIP3 mutations in PMBL patients could not be assessed due to the existence of only one WT TNFAIP3 PMBL patient treated with R-CHOP (Supplementary Table S7). Moreover, previously described prognostic impacts of TP53, FOXO1, or MYD88 mutations were not conﬁrmed (35, 50, 51), although the impact of speciﬁc deleterious mutations was not analyzed on its own.

In conclusion, NGS is increasingly accessible in academic research settings, but its possibilities in routine clinical settings have yet to be thoroughly harnessed. This study has shown that, by using a restricted set of genes, not only can well-known mutations be tracked, but novel or rare mutations can also be identiﬁed and potentially targeted as well. Detailing subtype-enriched gene and pathway mutations is critical for optimal understanding and treatment of DLBCL: here, we have added to the ﬁeld’s current knowledge of the genetic heterogeneity between DLBCL subtypes, and identiﬁed novel clinical and prognostic correlations, which might also have an impact on therapeutic decisions. NGS with a consensus targeted panel could contribute valuable information to multidisciplinary meetings and constitute a molecular breakthrough in the way treatment decisions are made, by providing personalized mutational proﬁles of actionable targets. Furthermore, although this study was performed on frozen tumor samples, which are of limited availability, the Lymphopanel was designed to be effective in FFPE samples as well, further cementing its capacity to play an essential role in clinical disease manage-

ment. In addition, our team has recently demonstrated that Lymphopanel NGS can be successfully performed using plasma-extracted cell-free circulating DNA, highlighting its feasibility and potential role in the monitoring of DLBCL (52). Taken together, these results serve as proof-of-principle that NGS with a consensus gene panel can alter the manner in which DLBCL patients are subclassiﬁed and treated.

Disclosure of Potential Conﬂicts of Interest

No potential conﬂicts of interest were disclosed.

Authors’ Contributions

Conception and design: S. Dubois, S. Mareshal, E. Boher, P. Bertrand, F. Desmots, C. Salles, H. Tilly, F. Jardin

Development of methodology: S. Dubois, P.-J. Vially, S. Mareshal, E. Boher, F. Jardin

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): E. Boher, P. Peyrouze, M. Figeye, T.J. Molina, C. Copie-Bergman, T. Petrella, D. Canioni, B. Coffrier, R. Delarue, A. Bosly, M. André, N. Ketzerer, G. Salles, H. Tilly

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Dubois, P.-J. Vially, S. Mareshal, E. Boher, P. Ruminy, J.-P. Jais, T. Lamy, D. Canioni, B. Fabiani, K. Leroy, F. Jardin


Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): P.-J. Vially, E. Boher, T. Fest, J. Brière

Study supervision: F. Jardin

Other (performing NGS experiments): C. Maingonnant

Acknowledgments

The authors thank Marie-Hélène Delfau, Camille Laurent, and Loïc Ysebaert for their critical review.

Grant Support

This study was funded by grants from the Institut National du cancer (INCa).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received September 23, 2015; revised December 14, 2015; accepted January 11, 2016; published OnlineFirst January 27, 2016.

References


